Aims To evaluate PIK3CA gene mutations and PIK3CA expression status in Chinese esophageal squamous cell carcinoma (ESCC) patients, and their correlation with clinicopathological characteristics and clinical outcomes. Methods Direct sequencing was applied to investigate mutations in exons 9 and 20 of PIK3CA in 406 Chinese ESCC patients. PIK3CA expression was evaluated using immunohistochemistry analysis. The associations of PIK3CA gene mutations and PIK3CA expression with clinicopathological characteristics and clinical outcome were examined. Results Thirty somatic point mutations (30/406, 7.4%) were identified in exon 9 whereas no mutations were detected in exon 20. PIK3CA mutations were not correlated with clinicopathological characteristics or clinical outcomes. However in the ESCC patients with family cancer history, PIK3CA mutations were independently correlated with worse overall survival (multivariate hazard ratio (HR) = 10.493, 95% CI: 2.432–45.267, P = 0.002). Compared to normal esophageal tissue, PIK3CA was significantly overexpressed in cancer tissue (P<0.001). PIK3CA overexpression was independently associated with higher risk of local recurrence (multivariate HR = 1.435, 95% CI: 1.040–1.979, P = 0.028). In female ESCC patients, PIK3CA overexpression was independently correlated with worse overall survival (multivariate HR = 2.341, 95% CI: 1.073–5.108, P = 0.033). Conclusions Our results suggest PIK3CA gene mutation and overexpression could act as biomarkers for individualized molecular targeted therapy for Chinese ESCC patients.
References
[1]
Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349: 2241–2252. doi: 10.1056/nejmra035010
[2]
Prabhu A, Obi KO, Rubenstein JH (2014) The Synergistic Effects of Alcohol and Tobacco Consumption on the Risk of Esophageal Squamous Cell Carcinoma: A Meta-Analysis. Am J Gastroenterol.
[3]
Lambert R, Hainaut P (2007) The multidisciplinary management of gastrointestinal cancer. Epidemiology of oesophagogastric cancer. Best Pract Res Clin Gastroenterol 21: 921–945. doi: 10.1016/j.bpg.2007.10.001
[4]
Zhang HL, Liu RL, Shi YT, Wang ZC, Wang BH, et al. (2009) [Analysis of the survival in patients after surgical resection of thoracic esophageal cancer]. Zhonghua Zhong Liu Za Zhi 31: 541–545.
[5]
Gartner JJ, Parker SC, Prickett TD, Dutton-Regester K, Stitzel ML, et al. (2013) Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci U S A 110: 13481–13486. doi: 10.1073/pnas.1304227110
[6]
Song Y, Li L, Ou Y, Gao Z, Li E, et al.. (2014) Identification of genomic alterations in oesophageal squamous cell cancer. Nature advance online publication.
[7]
Maeng CH, Lee J, van Hummelen P, Park SH, Palescandolo E, et al. (2012) High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations. PLoS One 7: e41655. doi: 10.1371/journal.pone.0041655
[8]
Hou J, Jiang D, Zhang J, Gavine PR, Xu S, et al. (2014) Frequency, characterization, and prognostic analysis of PIK3CA gene mutations in Chinese esophageal squamous cell carcinoma. Hum Pathol 45: 352–358. doi: 10.1016/j.humpath.2013.09.011
[9]
Wang WF, Xie Y, Zhou ZH, Qin ZH, Wu JC, et al. (2013) PIK3CA hypomethylation plays a key role in activation of the PI3K/AKT pathway in esophageal cancer in Chinese patients. Acta Pharmacol Sin 34: 1560–1567. doi: 10.1038/aps.2013.163
[10]
Shigaki H, Baba Y, Watanabe M, Murata A, Ishimoto T, et al. (2013) PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Clin Cancer Res 19: 2451–2459. doi: 10.1158/1078-0432.ccr-12-3559
[11]
Akagi I, Miyashita M, Makino H, Nomura T, Hagiwara N, et al. (2009) Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma. Int J Oncol 34: 767–775. doi: 10.3892/ijo_00000202
[12]
Mori R, Ishiguro H, Kimura M, Mitsui A, Sasaki H, et al. (2008) PIK3CA mutation status in Japanese esophageal squamous cell carcinoma. J Surg Res 145: 320–326. doi: 10.1016/j.jss.2007.03.044
[13]
Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497–5510. doi: 10.1038/onc.2008.245
[14]
Bader AG, Kang S, Zhao L, Vogt PK (2005) Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5: 921–929. doi: 10.1038/nrc1753
[15]
Samuels Y, Ericson K (2006) Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18: 77–82. doi: 10.1097/01.cco.0000198021.99347.b9
[16]
Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554. doi: 10.1126/science.1096502
[17]
Bader AG, Kang S, Vogt PK (2006) Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A 103: 1475–1479. doi: 10.1073/pnas.0510857103
[18]
Gymnopoulos M, Elsliger MA, Vogt PK (2007) Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A 104: 5569–5574. doi: 10.1073/pnas.0701005104
[19]
Zhang H, Chen D, Ringler J, Chen W, Cui QC, et al. (2010) Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. Cancer Res 70: 3996–4004. doi: 10.1158/0008-5472.can-09-3752
[20]
Tanaka H, Yoshida M, Tanimura H, Fujii T, Sakata K, et al. (2011) The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res 17: 3272–3281. doi: 10.1158/1078-0432.ccr-10-2882
[21]
Zou ZQ, Zhang LN, Wang F, Bellenger J, Shen YZ, et al. (2012) The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells. Mol Med Rep 5: 503–508. doi: 10.3892/mmr.2011.682
[22]
Mueller A, Bachmann E, Linnig M, Khillimberger K, Schimanski CC, et al. (2012) Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. Cancer Chemother Pharmacol 69: 1601–1615. doi: 10.1007/s00280-012-1869-z
[23]
Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, et al. (2014) Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 6: 377–387. doi: 10.1016/j.celrep.2013.12.035
[24]
Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, et al. (2012) PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget 3: 1566–1575.
[25]
Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, et al. (2011) PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 10: 558–565. doi: 10.1158/1535-7163.mct-10-0994
[26]
Zhu YL, Li Q, Gao JM, Li JS, He ZY, et al. (2013) A retrospective evaluation of radiotherapy for the treatment of local esophageal squamous cell carcinoma recurrence after initial complete surgical resection. J Investig Med 61: 34–39.
[27]
Murugan AK, Munirajan AK, Tsuchida N (2013) Genetic deregulation of the PIK3CA oncogene in oral cancer. Cancer Lett 338: 193–203. doi: 10.1016/j.canlet.2013.04.005
[28]
Greer EL, Brunet A (2005) FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24: 7410–7425. doi: 10.1038/sj.onc.1209086
[29]
Odajima T, Sasaki Y, Tanaka N, Kato-Mori Y, Asanuma H, et al. (2005) Abnormal beta-catenin expression in oral cancer with no gene mutation: correlation with expression of cyclin D1 and epidermal growth factor receptor, Ki-67 labeling index, and clinicopathological features. Hum Pathol 36: 234–241. doi: 10.1016/j.humpath.2004.12.009
[30]
Maeng CH, Lee J, van Hummelen P, Park SH, Palescandolo E, et al.. (2012) High-Throughput Genotyping in Metastatic Esophageal Squamous Cell Carcinoma Identifies Phosphoinositide-3-Kinase and BRAF Mutations. Plos One 7..
[31]
Shigaki H, Baba Y, Watanabe M, Murata A, Ishimoto T, et al. (2013) PIK3CA Mutation Is Associated with a Favorable Prognosis among Patients with Curatively Resected Esophageal Squamous Cell Carcinoma. Clinical Cancer Research 19: 2451–2459. doi: 10.1158/1078-0432.ccr-12-3559
[32]
Phillips WA, Russell SE, Ciavarella ML, Choong DY, Montgomery KG, et al. (2006) Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus. Int J Cancer 118: 2644–2646. doi: 10.1002/ijc.21706
[33]
Tanaka Y, Kanai F, Tada M, Asaoka Y, Guleng B, et al. (2006) Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients. Oncogene 25: 2950–2952. doi: 10.1038/sj.onc.1209311
[34]
Qiu W, Schonleben F, Li X, Ho DJ, Close LG, et al. (2006) PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 12: 1441–1446. doi: 10.1158/1078-0432.ccr-05-2173
[35]
Kang S, Bader AG, Vogt PK (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 102: 802–807. doi: 10.1073/pnas.0408864102
[36]
Chalhoub N, Baker SJ (2009) PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 4: 127–150. doi: 10.1146/annurev.pathol.4.110807.092311
[37]
Turati F, Edefonti V, Bosetti C, Ferraroni M, Malvezzi M, et al. (2013) Family history of cancer and the risk of cancer: a network of case-control studies. Ann Oncol 24: 2651–2656. doi: 10.1093/annonc/mdt280
[38]
Wu M, Zhang ZF, Kampman E, Zhou JY, Han RQ, et al. (2011) Does family history of cancer modify the effects of lifestyle risk factors on esophageal cancer? A population-based case-control study in China. Int J Cancer 128: 2147–2157. doi: 10.1002/ijc.25532
[39]
Zhu YF, Yu BH, Li DL, Ke HL, Guo XZ, et al. (2012) PI3K expression and PIK3CA mutations are related to colorectal cancer metastases. World J Gastroenterol 18: 3745–3751. doi: 10.3748/wjg.v18.i28.3745
[40]
Aleskandarany MA, Rakha EA, Ahmed MA, Powe DG, Paish EC, et al. (2010) PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Res Treat 122: 45–53. doi: 10.1007/s10549-009-0508-9
[41]
Abe A, Minaguchi T, Ochi H, Onuki M, Okada S, et al. (2013) PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma. Hum Pathol 44: 199–207. doi: 10.1016/j.humpath.2012.05.005
[42]
Liu JF, Zhou XK, Chen JH, Yi G, Chen HG, et al. (2010) Up-regulation of PIK3CA promotes metastasis in gastric carcinoma. World J Gastroenterol 16: 4986–4991. doi: 10.3748/wjg.v16.i39.4986
[43]
Tanno S, Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, et al. (2001) AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 61: 589–593. doi: 10.1016/s0016-5085(01)80193-1
[44]
Kikuchi J, Kinoshita I, Shimizu Y, Oizumi S, Nishimura M, et al. (2008) Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells. Br J Cancer 99: 2013–2019.
[45]
Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, et al. (2010) Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res 12: R40. doi: 10.1186/bcr2594
[46]
Riggio M, Polo ML, Blaustein M, Colman-Lerner A, Luthy I, et al. (2012) PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer. Carcinogenesis 33: 509–518. doi: 10.1093/carcin/bgr303
[47]
Generali D, Fox SB, Brizzi MP, Allevi G, Bonardi S, et al. (2008) Down-regulation of phosphatidylinositol 3′-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clin Cancer Res 14: 2673–2680. doi: 10.1158/1078-0432.ccr-07-1046
[48]
Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, et al. (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276: 9817–9824. doi: 10.1074/jbc.m010840200
